At present, a new round of scientific and technological revolution and industrial transformation is in the ascendant, and the pharmaceutical industry, which is closely related to people’s livelihood, has achieved unprecedented development. What will be the future of the research and application of medicine, from the early small molecule compounds to the widespread use of antibody drugs today?
The project of “Establishment and Application of Medical Technology Platform for Animal Embryonic Stem Cells to Promote Wound Healing” that shined in the 2nd Qiantang Star Innovation and Entrepreneurship Competition may bring us the answer.
“The research and development of biomedicine is a process from simple to complex,” Qian Jin was deeply impressed by the reporter’s unique professional rigorous attitude and honest and cold expression style unique to scientists, “medical technology has developed to this day, and the application of stem cells may become mainstream in the future.” ”
He has been deeply involved in the biotechnology industry for 18 years, and his doctor returned to China to start a business
As a distinguished researcher at the Hangzhou Branch of the Yangtze River Delta Research Institute of Tsinghua University, Qian Jin went to the United States to study further after obtaining a bachelor’s degree in genetics from Fudan University in Shanghai, and continued to work in the field of molecular developmental biology.
It was not until the past two years that the development situation of domestic medicine was very good, and Qian Jin had the idea of returning to China to start a business. “It takes an average of 12 years and $2.2 billion to launch a new drug,” Qian said, “The United States is relatively restrictive, has a longer cycle, and has greater costs, while the domestic pharmaceutical industry is now developing rapidly, with strong policy support and a broader space for development.” ”
In March last year, through the introduction of the Yangtze River Delta Research Institute of Tsinghua University, Zhejiang, Qian Jin returned to Hangzhou and founded Zhejiang Chuyuan Biotechnology Co., Ltd., specializing in the research of “R&D and application of stem cell technology and wound healing”, and in the same year, he participated in the Qiantang Star Innovation and Entrepreneurship Competition with the project of “Establishment and Application of Medical Technology Platform for Animal Embryonic Stem Cells to Promote Wound Healing”, won the winning award in one fell swoop, and successfully landed in Jianggan.
“When I first returned to China, I was not very familiar with all aspects, but the Jianggan district government attached great importance to it, and gave us a lot of help in terms of office space, administrative approval, and talent apartments,” Qian Jin said.
From biocosmetology to topical treatment, embryonic stem cell applications have a great impact
As a scientific research-led biotechnology company, Chuyuan Biotechnology has established a team of 18 people since its establishment one year ago, including 15 scientific researchers, accounting for 83%, nearly 500 square meters of independent laboratories, including more than 200 square meters of 1,000-level clean rooms, biochemical analysis rooms, microbial testing laboratories, etc., which can independently complete the research and production of various stem cell regenerative medicine projects.
In July this year, Chuyuan Biotechnology developed bio-beauty.The product has been marketed, using animal embryonic stem cells to achieve the effect of slowing down skin aging through information transmission.
The research on the application of embryonic stem cells does not stop there, Qian Jin said: “Embryonic stem cells have high activity, can grow rapidly in the early stage, and can be applied to a variety of wound healing, and have achieved remarkable results in animal experiments on organ repair. ”
However, high activity also makes the risk of tumors caused by genetic mutations a bottleneck in the field of embryonic stem cell research. For this, Qian Jin cleverly chose animal embryonic stem cells as the research object, “Animal cells cannot survive in the human body for a long time, and do not constitute a condition for tumor formation, so it is safe, and the research materials are easy to obtain, and it also avoids ethical controversy.” ”
In addition, the animal embryonic stem cell therapy technology pioneered by Qian Jin’s team has not observed an immune response in the experiment with the hospital so far.
The famous cell biologist Wilson once said, “The answer to every biological science question must be found in the cell.” “With the efforts of a generation of biological scientists such as Dr. Qian Jin, the application of stem cells may bring good news to patients in more fields in the future.
(Source: Zhejiang Online)